TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04885166

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Web-based placebo presentation
Description: This presentation will discuss the prevalence of psychological disorders in college students, their etiologies, psychiatric medications, and students' personal experiences navigating college with a diagnosis of an anxiety and learning disorder, respectively. Attention-deficit/hyperactivity disorder and stimulant medications will be addressed, but diversion and medication misuse will not be discussed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based simulation active intervention
Description: This intervention engages students in interactive discussions with virtual humans to (a) learn about the actual prevalence of NMUPS and diversion and their related risks, (b) practice using refusal strategies when approached for their medication in high-risk situations, and (c) understand how to effectively communicate with prescribers and avoid medication misuse.
Study: NCT04724759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine / Ketamine / Lidocaine
Description: Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics, as needed clinically. This includes administration of 5 mcg/kg/min of ketamine plus 0.5 - 1.0 µg/kg/hr of dexmedetomidine (Precedex) as a continuous infusion, started from induction to stop one hour before surgery is anticipated to end.
Study: NCT06187766

Intervention type: DIAGNOSTIC_TEST
Intervention: Social Media Addiction
Description: Social Media Addiction level will be determined by Bergen Social Media Addiction Scale
Study: NCT05786937

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides
Description: Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides
Description: Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides
Study: NCT06590064

Intervention type: DEVICE
Intervention: Non-invasive Blood Pressure Measurement
Description: Non-invasive Blood Pressure Measurement in Both Upper and Lower Limbs
Study: NCT06587789

Intervention type: DRUG
Intervention: Ribociclib
Description: Participants will receive ribociclib (at a dose of 400mg per day for 3 weeks, followed by 1 week off, 4 weeks for 1 cycle) plus physician-selected endocrine therapy (according to standard clinical practice, TAM or AI, with or without OFS).
Study: NCT06665022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: A neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode). For each stimulation condition (active, sham), each participant will perform two runs of N-back working memory task (baseline/pre-stimulation and during stimulation). Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
Study: NCT05786937

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Commercial ringer´s lactate solution
Description: Placebo
Study: NCT06114914

Intervention type: DIAGNOSTIC_TEST
Intervention: Tap Talk online program
Description: Online hand and speech motor testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Tap Talk online program
Description: Online hand and speech motor testing
Study: NCT06086704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluorofuranylnorprogesterone
Description: 18F-FFNP will be given by a slow infusion (approximately 2 minutes), and the dose administered will be approximately 7 mCi.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluorofuranylnorprogesterone
Description: 18F-FFNP will be given by a slow infusion (approximately 2 minutes), and the dose administered will be approximately 7 mCi.
Study: NCT06019598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Licorice
Description: Ecologic sweet licorice pastilles made from Glycyrrhiza glabra grown in Calabria, Italy, with a GA content of 29.9 ±2.0 mg/g.
Study: NCT06665022

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform two runs of N-back working memory task (baseline/pre-stimulation and during stimulation). Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
Study: NCT04630158

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SAF312 Placebo
Description: Topical ocular, suspension eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAF312
Description: Topical ocular, suspension eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAF312
Description: Topical ocular, suspension eye drops
Study: NCT05886387

Intervention type: OTHER
Intervention: High PEEP + Recruitment maneuvers
Description: The use of a High PEEP (positive end-expiratory pressure) level after recruiting collapsed alveoli can protect from mechanical ventilation associated lung injury

Intervention type: OTHER
Intervention: Standard PEEP. Low positive end-expriatory pressure
Description: Mechanical ventilation is managed with a low standard PEEP without recruitment manneuvers
Study: NCT06086704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluorofuranylnorprogesterone
Description: 18F-FFNP will be given by a slow infusion (approximately 2 minutes), and the dose administered will be approximately 7 mCi.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emissions Tomography / Magnetic Resonance Imaging
Description: Breast specific PET/MRI data will be acquired using a 3T simultaneous PET/MRI scanner (Signa PET/MR, GE Healthcare)
Study: NCT04496115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness training
Study: NCT05396521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: Group 2 (experimental) will receive standard of care physical therapy to be done with blood flow restriction therapy (BFR). This method includes standard of care physical therapy while occluding blood flow.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Physical Therapy
Description: Group 1 (Control) will receive standard of care physical therapy.
Study: NCT04762498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: IV dose of pegloticase q4 weeks co-administered with weekly oral methotrexate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: IV dose of pegloticase q4 weeks co-administered with weekly oral methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: 15 mg oral dose methotrexate administered weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: 15 mg oral dose methotrexate administered weekly
Study: NCT06365918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG2025
Description: Given by Intraperitoneal
Study: NCT06077838

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RELAXaHEAD Smartphone App Version 1
Description: RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts.
Study: NCT06696599

Intervention type: PROCEDURE
Intervention: Serum and corporal irisin
Description: measure serum and corporal irisin
Study: NCT06698692

Intervention type: DRUG
Intervention: Trilaciclib Injection [Cosela]
Description: Trilaciclib Combined chemoradiotherapy
Study: NCT06699745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: In studies, white noise was used as a sedative in infants. It was not used in older children. In school-age children, white noise will be used to reduce fear, anxiety and pain during the endoscopy procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: white noise intervention
Description: White noise will be played at a decibel level appropriate for the children in the group.
Study: NCT06699329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: multiple doses, oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: multiple doses, oral tablet
Study: NCT06699459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome
Description: ②LV: 400mg/m2, intravenous infusion, Q2W, d1; ③5-FU: 2400 mg/m2, continuous intravenous infusion, Q2W, d1-2;

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: ① Capecitabine, 1250mg/m2 orally, bid, Q3W, d1-14;
Study: NCT06699498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benmelstobart
Description: 1200mg, D1, IV,q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 10mg，D1-14，po，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60mg/m2， D1， IV，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for Injection （Albumin Bound）
Description: 260mg/m2，IVgtt ，D1，q3w
Study: NCT06698354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Assisted Hypnotherapy
Description: Virtual Reality-Assisted Hypnotherapy utilizes HypnoVR software delivered through VR glasses to provide a relaxing virtual environment. The intervention is integrated into a standard physical therapy program, with participants receiving 20-minute VR-assisted hypnotherapy sessions during each of the 15 supervised physical therapy sessions over a 3-week period. This approach aims to improve pain management, quality of life, and adherence to treatment in patients with chronic low back pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Participants in the control group will undergo a standard physical therapy program focused on the cervical region, consisting of 15 sessions over 3 weeks. Each session will be supervised by physiotherapists in a clinical setting and will include traditional physical therapy techniques such as therapeutic exercises
Study: NCT06699303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g / 100 g for infants in the control group in diaper dermatitis care
Description: In diaper dermatitis care, it was planned to use their mothers' milk for the babies in the experimental group and diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100g for the babies in the control group. The reason why diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g is preferred is that it is the most frequently used cream in cases of uncomplicated diaper dermatitis. The mothers of the babies in the control group will be asked to wash and dry the baby's diaper with soap and water during each diaper change and then apply diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g. Mothers will be asked to record any new signs and symptoms that develop during the treatment and to inform the investigators will be asked to provide information. Positive and negative effects of treatment will also be recorded.
Study: NCT06442748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam is usually preferred in brain tumor-related epilepsy. Levetiracetam is a second-generation antiepileptic drug that binds to synaptic vesicle glycoprotein SV2A, which interferes with the release of neurotransmitters from the synaptic vesicle and control seizure by multiple mechanisms.

Intervention type: DRUG
Group type: OTHER
Intervention: Levetiracetam
Description: Levetiracetam is usually preferred in brain tumor-related epilepsy. Levetiracetam is a second-generation antiepileptic drug that binds to synaptic vesicle glycoprotein SV2A, which interferes with the release of neurotransmitters from the synaptic vesicle and control seizure by multiple mechanisms.
Study: NCT06424340

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-dNPM1-TCR.1
Description: T Cell Receptor (TCR) T cell therapy
Study: NCT05620979

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation.
Description: Providing financial navigation to blood cancer survivors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation.
Description: Providing financial navigation to blood cancer survivors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation.
Description: Providing financial navigation to blood cancer survivors.
Study: NCT06077838

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RELAXaHEAD Smartphone App Version 2
Description: RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts. This version also contains audio materials.
Study: NCT06086704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emissions Tomography / Magnetic Resonance Imaging
Description: Breast specific PET/MRI data will be acquired using a 3T simultaneous PET/MRI scanner (Signa PET/MR, GE Healthcare)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emissions Tomography / Magnetic Resonance Imaging
Description: Breast specific PET/MRI data will be acquired using a 3T simultaneous PET/MRI scanner (Signa PET/MR, GE Healthcare)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: hormone based chemotherapy that reduces estrogen, 1 mg anastrozole once daily by mouth for a minimum of 14 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: Venous blood samples will be collected at multiple timepoints (e.g., 5, 10, 20, 30, and 45 min after 18F-FFNP injection to determine parent and metabolite fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA-approved gadolinium-based intravenous contrast agent
Description: FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA-approved gadolinium-based intravenous contrast agent
Description: FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA-approved gadolinium-based intravenous contrast agent
Description: FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study
Study: NCT06281652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Go classes
Description: Classes of board games (Go), performed in groups of 6-10 subjects, once a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Go classes
Description: Classes of board games (Go), performed in groups of 6-10 subjects, once a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chess classes
Description: Classes of board games (Chess), performed in groups of 6-10 subjects, once a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chess classes
Description: Classes of board games (Chess), performed in groups of 6-10 subjects, once a week
Study: NCT04192773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Lidocaine
Description: IV lidocaine will be administered pre-fMRI and post-FMRI with each subject acting as their own control
Study: NCT05068791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 0.36 mg/kg will be administered orally to participants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan
Description: 2.6 mg/kg of active placebo will be administered orally to participants
Study: NCT04696289

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standardized catheterization assessment
Description: There are four components to the pulmonary vein assessment.~1. Angiography: pulmonary artery wedge injection and/or selective pulmonary vein injection.~2. Intravascular ultrasound: manual pullback of IVUS catheter from lobar segment to left atrium.~3. Pressure assessment: pulmonary vein pressure (mmHg) measured before and after (if applicable) intervention.~4. Compliance testing: the compliance of the vein will be measured using a compliant conventional balloon.
Study: NCT06288230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vesemnogene lantuparvovec
Description: Exploratory study evaluating the safety and efficacy of vesemnogene lantuparvovec in patients with SMA.
Study: NCT01937663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711
Study: NCT05980871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: doxycycline (100 mg orally twice daily for 7 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: doxycycline (100 mg orally twice daily for 7 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Ceftriaxone (1g intramuscularly once)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzathine penicillin G
Description: benzathine penicillin G (2.4 MU intramuscularly once)
Study: NCT06352060

Intervention type: OTHER
Intervention: No intervention or administration will be performed due to the observational nature of the study
Description: Charts of patients enrolled in the study will be reviewed for an initial monitoring method and any changes in management.

Intervention type: OTHER
Intervention: No intervention or administration will be performed due to the observational nature of the study
Description: Charts of patients enrolled in the study will be reviewed for an initial monitoring method and any changes in management.
Study: NCT05785286

Intervention type: OTHER
Intervention: BPH 3-item questionnaire
Description: BPH 3-item questionnaire. The questionnaire consists of only three items. A raw score ranging from 0 to 5 is assigned to each of the items, giving a final total score varying from 0 (no symptom) to 15 (very symptomatic).

Intervention type: OTHER
Intervention: BPH 3-item questionnaire
Description: BPH 3-item questionnaire. The questionnaire consists of only three items. A raw score ranging from 0 to 5 is assigned to each of the items, giving a final total score varying from 0 (no symptom) to 15 (very symptomatic).
Study: NCT04999384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN4005-dose level 0
Description: 50mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN4005-dose level 1
Description: 100mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN4005-dose level 2
Description: 200mg BID
Study: NCT05825365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selumetinib
Description: Selumetinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Transfer to selumetinib on REiNS-defined PD)
Study: NCT05687292

Intervention type: DEVICE
Intervention: Clinical decision support system (CDSS) for ventilator weaning
Description: A clinical decision support system (CDSS) will be integrated into a software program (the T3 platform) that is present on all patient bedside computers. The T3 platform is a tool that compiles data from a patient's existing physiologic monitors, ventilator, and laboratory results and graphically displays them on a bedside monitor. The CDSS will be active on all patients receiving mechanical ventilation, but primary use and evaluation will focus on patients meeting study criteria. Twice daily (on morning rounds and evening rounds), patients will be screened for eligibility. During each rounds, teams will review the CDSS and associated risk analytics data used to inform the associated recommendations for ventilator weaning, extubation readiness assessment, and extubation. The clinical team will consider the CDSS in decision making around ventilator weans. If the decision is made not to follow the CDSS recommendations, the clinician will complete a brief survey with rationale.
Study: NCT05598957

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D Binding protein
Description: Vitamin D-free and bioavailable metabolites were calculated by using Bikle and Vermeulen methods with using albumin, 25-OH vitamin D, vitamin D binding protein (ELİSA kit) levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D Binding protein
Description: Vitamin D-free and bioavailable metabolites were calculated by using Bikle and Vermeulen methods with using albumin, 25-OH vitamin D, vitamin D binding protein (ELİSA kit) levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D Binding protein
Description: Vitamin D-free and bioavailable metabolites were calculated by using Bikle and Vermeulen methods with using albumin, 25-OH vitamin D, vitamin D binding protein (ELİSA kit) levels
Study: NCT06523699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant glycosylated human interleukin-7
Description: Provided by RevImmune

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic cell transplant
Description: Standard of care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous hematopoietic cell transplant
Description: Standard of care